Biomarin Good Will from 2010 to 2025

BMRN Stock  USD 71.24  0.36  0.50%   
Biomarin Pharmaceutical Good Will yearly trend continues to be very stable with very little volatility. Good Will is likely to drop to about 124.9 M. Good Will is an intangible asset that arises when Biomarin Pharmaceutical acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors. View All Fundamentals
 
Good Will  
First Reported
2004-09-30
Previous Quarter
196.2 M
Current Value
196.2 M
Quarterly Volatility
81.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.2 M, Interest Expense of 17.9 M or Selling General Administrative of 558.9 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Good Will Growth Pattern

Below is the plot of the Good Will of Biomarin Pharmaceutical over the last few years. It is an intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors. Biomarin Pharmaceutical's Good Will historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Good Will10 Years Trend
Slightly volatile
   Good Will   
       Timeline  

Biomarin Good Will Regression Statistics

Arithmetic Mean148,575,145
Geometric Mean126,630,103
Coefficient Of Variation47.48
Mean Deviation63,733,550
Median196,199,000
Standard Deviation70,546,011
Sample Variance4976.7T
Range180.6M
R-Value0.73
Mean Square Error2518.6T
R-Squared0.53
Significance0
Slope10,763,684
Total Sum of Squares74651.1T

Biomarin Good Will History

2025124.9 M
2024225.6 M
2020196.2 M
2015197 M
201354.3 M
201151.5 M
201045.1 M

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Good Will, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Good Will225.6 M124.9 M
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.449
Earnings Share
2.2
Revenue Per Share
15.018
Quarterly Revenue Growth
0.156
Return On Assets
0.0515
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.